AnaptysBio, Inc. (ANAB)
Nasdaq: ANAB · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2006
Who owns AnaptysBio, Inc.
As filed with the SECHolders of 5% or more
2
Blackrock, Inc. holds 6.2% of Common Stock, as its SCHEDULE 13G/A filed Apr 17, 2025 says.
Directors and officers
14
report now, of 25 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock · 8.4% in Feb 5, 2025
Sirenia Capital Management LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 6.7% in May 15, 2026
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Nov 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.2% in May 12, 2025
Morgan Stanley
SCHEDULE 13G/A · filed Feb 11, 2026 · Common Stock · reported falling below 5%, from 6.3% in Aug 5, 2025
Mathew P. Arens
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.01 par value · reported falling below 5%, from 7.71% in Aug 7, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Jan 16, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.1% in Sep 23, 2025
James N. Topper
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%, from 5.4% in Feb 14, 2025
Fmr LLC
SCHEDULE 13G/A · filed Jun 6, 2025 · COMMON STOCK · reported falling below 5%, from 6.2% in May 12, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.7% in May 15, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.23% in Jul 29, 2025
Fairmount Funds Management LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.5% in Dec 18, 2024
What ANAB reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 3, 2026.
Insider tradesForm 4
42sales
0purchases
11sales on a scheduled plan
8people selling
$9.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 42 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Faga Daniel | President, CEO | 13 | $2.8M | 0 | 0 | $0 |
| Loumeau Eric J | CHIEF LEGAL OFFICER | 12 | $2.7M | 6 | 0 | $0 |
| Mulroy Dennis | CHIEF FINANCIAL OFFICER | 6 | $1.5M | 3 | 0 | $0 |
| Schmid John P. | director | 3 | $1.2M | 0 | 0 | $0 |
| Lizzul Paul F. | Chief Medical Officer | 4 | $500,000 | 1 | 0 | $0 |
| Marquet Magda | director | 2 | $500,000 | 0 | 0 | $0 |
| Renton Hollings | director | 1 | $200,000 | 1 | 0 | $0 |
| Ware J. Anthony | director | 1 | $200,000 | 0 | 0 | $0 |